UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that ...

How big is Syringes Market in 2026? Sales in the syringes market are projected to grow at 4.3% CAGR, with the market size rising from USD 21.9 billion in 2025 to USD 22.8 billion in 2026 and reaching ...

With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache Eli Lilly and ...

Enabling your Pre-filled Syringe (PFS) drug development is our top priority. At Aptar Pharma, we have built a comprehensive platform of PFS closure components for your biotech drugs, vaccines and ...

What is Comprehensive Harm Reduction? Comprehensive Harm Reduction (CHR) is a set of public health services. CHR is designed to reduce the negative impact of drug use. It helps prevent HIV, hepatitis ...